Taken together, these results suggested that ILT4 blockade enhanced ICI activity in both TKI-resistant and EGFR wild-type NSCLC cells, affording a potential strategy to overcome ICI resistance in these patients. The gene discussed is LILRB2; the disease is non-small cell lung carcinoma.